These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 19488064)

  • 1. Corticosteroid effects on blood gene expression in Duchenne muscular dystrophy.
    Lit L; Sharp FR; Apperson M; Liu DZ; Walker WL; Liao I; Xu H; Ander BP; Wong B
    Pharmacogenomics J; 2009 Dec; 9(6):411-8. PubMed ID: 19488064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.
    Moxley RT; Ashwal S; Pandya S; Connolly A; Florence J; Mathews K; Baumbach L; McDonald C; Sussman M; Wade C; ;
    Neurology; 2005 Jan; 64(1):13-20. PubMed ID: 15642897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of deflazacort on cardiac and sternocleidomastoid muscles in Duchenne muscular dystrophy: a magnetic resonance imaging study.
    Mavrogeni S; Papavasiliou A; Douskou M; Kolovou G; Papadopoulou E; Cokkinos DV
    Eur J Paediatr Neurol; 2009 Jan; 13(1):34-40. PubMed ID: 18406648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols.
    Biggar WD; Politano L; Harris VA; Passamano L; Vajsar J; Alman B; Palladino A; Comi LI; Nigro G
    Neuromuscul Disord; 2004 Sep; 14(8-9):476-82. PubMed ID: 15336688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Developing standardized corticosteroid treatment for Duchenne muscular dystrophy.
    Guglieri M; Bushby K; McDermott MP; Hart KA; Tawil R; Martens WB; Herr BE; McColl E; Wilkinson J; Kirschner J; King WM; Eagle M; Brown MW; Willis T; Hirtz D; Shieh PB; Straub V; Childs AM; Ciafaloni E; Butterfield RJ; Horrocks I; Spinty S; Flanigan KM; Kuntz NL; Baranello G; Roper H; Morrison L; Mah JK; Manzur AY; McDonald CM; Schara U; von der Hagen M; Barohn RJ; Campbell C; Darras BT; Finkel RS; Vita G; Hughes I; Mongini T; Pegoraro E; Wicklund M; Wilichowski E; Bryan Burnette W; Howard JF; McMillan HJ; Thangarajh M; Griggs RC
    Contemp Clin Trials; 2017 Jul; 58():34-39. PubMed ID: 28450193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corticosteroids in Duchenne muscular dystrophy: a reappraisal.
    Wong BL; Christopher C
    J Child Neurol; 2002 Mar; 17(3):183-90. PubMed ID: 12026233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade.
    Biggar WD; Harris VA; Eliasoph L; Alman B
    Neuromuscul Disord; 2006 Apr; 16(4):249-55. PubMed ID: 16545568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect.
    Balaban B; Matthews DJ; Clayton GH; Carry T
    Am J Phys Med Rehabil; 2005 Nov; 84(11):843-50. PubMed ID: 16244521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deflazacort treatment of Duchenne muscular dystrophy.
    Biggar WD; Gingras M; Fehlings DL; Harris VA; Steele CA
    J Pediatr; 2001 Jan; 138(1):45-50. PubMed ID: 11148511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy.
    Bonifati MD; Ruzza G; Bonometto P; Berardinelli A; Gorni K; Orcesi S; Lanzi G; Angelini C
    Muscle Nerve; 2000 Sep; 23(9):1344-7. PubMed ID: 10951436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
    Guglieri M; Bushby K; McDermott MP; Hart KA; Tawil R; Martens WB; Herr BE; McColl E; Speed C; Wilkinson J; Kirschner J; King WM; Eagle M; Brown MW; Willis T; Griggs RC; ; Straub V; van Ruiten H; Childs AM; Ciafaloni E; Shieh PB; Spinty S; Maggi L; Baranello G; Butterfield RJ; Horrocks IA; Roper H; Alhaswani Z; Flanigan KM; Kuntz NL; Manzur A; Darras BT; Kang PB; Morrison L; Krzesniak-Swinarska M; Mah JK; Mongini TE; Ricci F; von der Hagen M; Finkel RS; O'Reardon K; Wicklund M; Kumar A; McDonald CM; Han JJ; Joyce N; Henricson EK; Schara-Schmidt U; Gangfuss A; Wilichowski E; Barohn RJ; Statland JM; Campbell C; Vita G; Vita GL; Howard JF; Hughes I; McMillan HJ; Pegoraro E; Bello L; Burnette WB; Thangarajh M; Chang T
    JAMA; 2022 Apr; 327(15):1456-1468. PubMed ID: 35381069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deflazacort versus prednisone/prednisolone for maintaining motor function and delaying loss of ambulation: A post HOC analysis from the ACT DMD trial.
    Shieh PB; Mcintosh J; Jin F; Souza M; Elfring G; Narayanan S; Trifillis P; Peltz SW; Mcdonald CM; Darras BT;
    Muscle Nerve; 2018 Nov; 58(5):639-645. PubMed ID: 30028519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxandrolone enhances skeletal muscle myosin synthesis and alters global gene expression profile in Duchenne muscular dystrophy.
    Balagopal P; Olney R; Darmaun D; Mougey E; Dokler M; Sieck G; Hammond D
    Am J Physiol Endocrinol Metab; 2006 Mar; 290(3):E530-9. PubMed ID: 16263771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corticosteroid Treatment and Growth Patterns in Ambulatory Males with Duchenne Muscular Dystrophy.
    Lamb MM; West NA; Ouyang L; Yang M; Weitzenkamp D; James K; Ciafaloni E; Pandya S; DiGuiseppi C;
    J Pediatr; 2016 Jun; 173():207-213.e3. PubMed ID: 27039228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial.
    Beenakker EA; Fock JM; Van Tol MJ; Maurits NM; Koopman HM; Brouwer OF; Van der Hoeven JH
    Arch Neurol; 2005 Jan; 62(1):128-32. PubMed ID: 15642859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prednisone and deflazacort in Duchenne muscular dystrophy: a patient perspective and plain language summary publication of the Cincinnati study.
    Wong BL; Cook T; Miller H
    J Comp Eff Res; 2022 Aug; 11(11):779-786. PubMed ID: 35713895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world outcomes of long-term prednisone and deflazacort use in patients with Duchenne muscular dystrophy: experience at a single, large care center.
    Marden JR; Freimark J; Yao Z; Signorovitch J; Tian C; Wong BL
    J Comp Eff Res; 2020 Feb; 9(3):177-189. PubMed ID: 31922454
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparing Deflazacort and Prednisone in Duchenne Muscular Dystrophy.
    Biggar WD; Skalsky A; McDonald CM
    J Neuromuscul Dis; 2022; 9(4):463-476. PubMed ID: 35723111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta-analysis of disease progression rates in recent multicenter clinical trials.
    McDonald CM; Sajeev G; Yao Z; McDonnell E; Elfring G; Souza M; Peltz SW; Darras BT; Shieh PB; Cox DA; Landry J; Signorovitch J;
    Muscle Nerve; 2020 Jan; 61(1):26-35. PubMed ID: 31599456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
    Smith EC; Conklin LS; Hoffman EP; Clemens PR; Mah JK; Finkel RS; Guglieri M; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; Kerchner L; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; Gordish-Dressman H; Hagerty L; Dang UJ; Damsker JM; Schwartz BD; Mengle-Gaw LJ; McDonald CM;
    PLoS Med; 2020 Sep; 17(9):e1003222. PubMed ID: 32956407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.